Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer

By Riedel Richard F   Febbo Phillip G  

Future Oncology, Vol. 1, Iss. 4, 2005-08 ,pp. : 461-466

Future Medicine

Access to resources Recommend Favorite

Patterns of epidermal growth factor receptor mutation in non-small-cell lung cancers in the Gulf region

By                

Molecular and Clinical Oncology, Vol. 3, Iss. 6, 2015-01 ,pp. : 1371-1374

Science Publishers

Access to resources Recommend Favorite

Interstitial lung disease in patients with non-small-cell lung cancer treated with epidermal growth factor receptor inhibitors

By Tsuboi Masahiro   Chevalier Thierry  

Medical Oncology, Vol. 23, Iss. 2, 2006-06 ,pp. : 161-170

Humana Press, Inc

Access to resources Recommend Favorite

Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy

By Giaccone Giuseppe   Iacona Renee   Fandi Abderrahim   Janas Mette   Ochs Judith   Herbst Roy   Johnson David  

Journal of Cancer Research and Clinical Oncology, Vol. 135, Iss. 3, 2009-03 ,pp. : 467-476

Springer Publishing Company

Access to resources Recommend Favorite

Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer

By        

Molecular Medicine Reports, Vol. 10, Iss. 2, 2014-01 ,pp. : 931-938

Spandidos Publications

Access to resources Recommend Favorite